Growth highlights Labcorp is a global leader in diagnostics and drug development with over 60,000 employees and a revenue footprint exceeding $10B. The company recently expanded its central laboratory and biomarker capabilities through the MLM Medical Labs acquisition, signaling a bold growth and capacity-building strategy that can open cross-sell opportunities in clinical trials, biomarker testing, and global central lab services.

AI and specialty emphasis Investor day announcements emphasize AI-driven and specialty testing as key growth drivers through 2029, presenting a compelling case for partnerships in data analytics, automation, and advanced diagnostics to improve turnaround times, accuracy, and patient outcomes across hospitals, pharma clients, and biotechs.

Global scale With operations in over 100 countries and a strategy framed around global scale and sustainable cash flow, Labcorp offers multinational health systems and pharmaceutical developers a single, integrated partner for global trial management, harmonized diagnostics, and standardized biomarker workflows.

Strategic fit Recent high-profile M&A activity and a diversified service mix position Labcorp as a potential buyer or partner for diagnostic and laboratory outsourcing, clinical trial support, and centralized biomarker services across continents, which could be leveraged to upsell end-to-end lab solutions to pharmaceutical and contract research organizations.

Tech-enabled selling Labcorp’s tech stack including Power BI, Tableau, Google Cloud and enterprise systems indicates a data-driven approach to decision making and client delivery. This suggests opportunities to offer advanced analytics, dashboards, and integrated data solutions to prospective hospital and pharma clients to optimize test utilization, reporting, and study oversight.